Financial News, Analysis and Data, FNArena

FNArena

Financial News, Analysis and Data

Online financial media company focused on Australian equities, with a global perspective

Equity Bottom-Up

<ul><li>Wesfarmers offers resilience and quality management to execute through the macro cycle, with digital and agentic levers supporting FY28 earnings acceleration.</li><li> Wesfarmers&rsquo; retail resilience shines through a tougher cycle Digital, AI and automation unlock the next leg of growth Margin resilience sets Wesfarmers apart from retail rivals Valuation de-rating offers investors a fresh entry point</li></ul>

Wesfarmers offers resilience and quality management to execute through the macro cycle, with digital and agentic levers supporting FY28 earnings acceleration. Wesfarmers&rsquo; retail resilience shines through a tougher cycle Digital, AI and automation unlock the next leg of growth Margin resilience sets Wesfarmers apart from retail rivals Valuation de-rating offers investors a fresh entry point

JB Hi-Fi Ltd - Appreciating Wesfarmers' Quality & Resilience

Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>Hansoh Pharmaceutical announced that a new indication of Xinyue has been included in the Priority Review. Astellas Pharma announced positive update from the Phase 3 EV-302 clinical trial.</li>
<li>CSL has received EU approval for HAE drug, Andemry. Imugene announce more positive results from its Phase 1b trial of azer-cel, an allogenic therapy in relapsed/refractory diffuse large B-cell lymphoma.</li>
<li>LigaChem Bio signed technology transfer agreement for a new anticancer target antibody for the development of ADC candidates with Daan Biotherapeutics. Lupin received FDA approval for generic Atrovent Nasal Spray.</li>
</ul>


Hansoh Pharmaceutical announced that a new indication of Xinyue has been included in the Priority Review. Astellas Pharma announced positive update from the Phase 3 EV-302 clinical trial.
CSL has received EU approval for HAE drug, Andemry. Imugene announce more positive results from its Phase 1b trial of azer-cel, an allogenic therapy in relapsed/refractory diffuse large B-cell lymphoma.
LigaChem Bio signed technology transfer agreement for a new anticancer target antibody for the development of ADC candidates with Daan Biotherapeutics. Lupin received FDA approval for generic Atrovent Nasal Spray.


APAC Healthcare Weekly (Feb 16)- Hansoh Pharma, Astellas Pharma, CSL, Imugene, LigaChem Bio, Lupin

New Zealand Professional Investment Services Firm, Forsyth Barr

Forsyth Barr

New Zealand Professional Investment Services Firm

We are proud to be a New Zealand owned firm, with 21 offices throughout the country and over 300 employees. We assist personal, institutional and corporate clients providing a full range of investment services.

Forsyth Barr is a foundation New Zealand Exchange firm (NZX) and accredited market participant. We have been confirmed by the Financial Markets Authority as a Qualifying Financial Entity (QFE).

Research is the cornerstone of our advice. We have one of New Zealand's leading teams of analysts. Our global affiliations ensure comprehensive research coverage of all major investment markets.

Sky Network Television / Equity Bottom-Up

<ul>
<li>Sky TV (SKT) reported a solid FY26 result, with adjusted EBITDA up +6% year-on-year and modestly ahead of our expectations.</li>
<li>The key highlight of the result however is strong free cash flow and dividends—exactly what investors are looking for from SKT.</li>
<li>SKT has declared a final FY26 dividend of NZ17cps, taking total FY26 dividends to NZ32cps (fully imputed), ahead of our NZ30cps estimate.</li>
</ul>


Sky TV (SKT) reported a solid FY26 result, with adjusted EBITDA up +6% year-on-year and modestly ahead of our expectations.
The key highlight of the result however is strong free cash flow and dividends—exactly what investors are looking for from SKT.
SKT has declared a final FY26 dividend of NZ17cps, taking total FY26 dividends to NZ32cps (fully imputed), ahead of our NZ30cps estimate.


Sky TV (SKT): FY26 Result–Initial Impressions

<ul><li>The quality growth stock landscape in New Zealand is dominated by F&amp;P Healthcare (FPH), Mainfreight (MFT), and EBOS Group (EBO).</li><li>Each offers attractive investment attributes with strong track records of execution.</li><li>Structurally, we like all three companies, with each well positioned for continued growth and favourable returns. </li></ul>

The quality growth stock landscape in New Zealand is dominated by F&amp;P Healthcare (FPH), Mainfreight (MFT), and EBOS Group (EBO).Each offers attractive investment attributes with strong track records of execution.Structurally, we like all three companies, with each well positioned for continued growth and favourable returns. 

Quality Growth Stocks: F&P Healthcare, Mainfreight and EBOS Group - The Creme De La Creme

<ul>
<li>We expect Sky TV (SKT) to report a solid FY26 result on Friday 28 August 2026.</li>
<li>We believe a dividend target of &gt;NZ35cps by FY29 would be taken well by the market.</li>
<li>SKT is also in a very attractive net cash position (NZ$60m—NZ$70m); clarity on how it intends to return this to shareholders (or invest at attractive returns) would be welcome.</li>
</ul>


We expect Sky TV (SKT) to report a solid FY26 result on Friday 28 August 2026.
We believe a dividend target of &gt;NZ35cps by FY29 would be taken well by the market.
SKT is also in a very attractive net cash position (NZ$60m—NZ$70m); clarity on how it intends to return this to shareholders (or invest at attractive returns) would be welcome.


Australia

EBOS Group Limited supplies and distributes medical consumable products and equipment to the hospital and primary care sectors of the New Zealand and Australian healthcare markets. The Company's products include diagnostic instruments, surgical instruments and prosthesis, feminine protection, anesthetic equipment, and other consumer products.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

EBOS Group (EBO AU)

JB Hi-Fi Ltd - Appreciating Wesfarmers' Quality & Resilience

Wesfarmers offers resilience and quality management to execute through the macro cycle, with digital and agentic levers supporting FY28 earnings...

FNArena

APAC Healthcare Weekly (Feb 16)- Hansoh Pharma, Astellas Pharma, CSL, Imugene, LigaChem Bio, Lupin

APAC healthcare companies continued to get approvals for new products and initiates clinical trials. The companies continued with acquisitions and...

Tina Banerjee

Sky TV (SKT): FY26 Result–Initial Impressions

Sky TV (SKT) reported a solid FY26 result, with adjusted EBITDA up +6% year-on-year and modestly ahead of our expectations. The key highlight of...

Forsyth Barr

Quality Growth Stocks: F&P Healthcare, Mainfreight and EBOS Group - The Creme De La Creme

The quality growth stock landscape in New Zealand is dominated by F&P Healthcare (FPH), Mainfreight (MFT), and EBOS Group (EBO).

Forsyth Barr

Sky TV FY26 Preview—A Lot to Watch

We expect Sky TV (SKT) to report a solid FY26 result on Friday 28 August 2026. We believe a dividend target of >NZ35cps by FY29 would be taken...

Forsyth Barr

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)